Key statistics
As of last trade Akeso Inc (9926:HKG.HS) traded at 72.15, -7.08% below its 52-week high of 77.65, set on Oct 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.80 |
---|---|
High | 74.50 |
Low | 71.95 |
Bid | 72.10 |
Offer | 72.20 |
Previous close | 73.25 |
Average volume | 7.61m |
---|---|
Shares outstanding | 897.56m |
Free float | 668.34m |
P/E (TTM) | -- |
Market cap | 63.14bn HKD |
EPS (TTM) | -0.9412 HKD |
Data delayed at least 15 minutes, as of Nov 22 2024 05:28 GMT.
More ▼
Press releases
- Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
- Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
More ▼